Sareum’s small molecule drug discovery expertise builds value by developing drug candidates, focused on cancer and autoimmune disease, for licencing to pharmaceutical and biotechnology companies.
13 May 2021
23 April 2021
25 March 2021
25 March 2021
The potential of Sareum's SDC-1801 TYK2/JAK1 inhibitor in the fight against Covid-19
IMC Half Year Results, Apr 2021 (Slides)
LSX World Congress, Feb 2021 (Video)
IMC Full Year Results, Oct 2020 (Slides)
Proactive Investors, Aug 2020 (Video)
Sareum Limited
Unit 2A, Langford Arch
London Road, Pampisford
Cambridge CB22 3FX
United Kingdom
tel: +44 (0) 1223 497700
fax: +44 (0) 1223 497701
